PLENARY KEYNOTE SESSIONS

Tuesday, March 26

CONVERGENCE OF ARTIFICIAL INTELLIGENCE AND GENOMICS

8:00 am Chairperson's Remarks
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing

8:05 am Plenary Keynote Introduction
Damian VerdnikDamian Verdnik, PhD, Director, Diagnostics, Dx PMO, Invetech


8:15 am The Genomics/AI Revolution: A Fireside Chat with Kari Stefansson
Kari StefanssonKari Stefansson, MD, PhD, CEO, deCODE genetics
Kevin DaviesKevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Almost 30 years ago, Kari Stefansson returned home to his native Iceland with a vision to unleash the untapped potential of a precious genomics resource: his fellow Icelanders. The founding CEO of deCODE Genetics built a groundbreaking organization that fueled major advances in uncovering the genomics basis of many rare and common genetic diseases and cancers. After weathering some turbulent financial storms, Stefansson secured deCODE’s acquisition by Amgen in 2010. For the past decade, deCODE has provided the genomics engine to spur Amgen’s drug development and clinical programs. In this fireside chat, Stefansson will share stories and insights about deCODE’s incredible journey, the future of genomic medicine and the myriad applications of AI in genomic and biopharma research.

8:45 am PANEL DISCUSSION: AI and Genomics Come Together
PANEL MODERATOR:
Kevin DaviesKevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Artificial intelligence (AI) promises to enable the analysis of trillions of genomic, molecular, clinical, and epidemiological data, offering unprecedented insights into health and disease, the development of drugs and diagnostics, and empowering precision medicine. Our distinguished panel will review the opportunities, challenges, and innovations in applying emerging AI tools to biological data, and their potential to revolutionize drug development, diagnostics, and precision medicine.

PANELISTS:
Kari StefanssonKari Stefansson, MD, PhD, CEO, deCODE genetics
Atul ButteAtul Butte, PhD, Chan & Zuckerberg Distinguished Professor & Director, University of California, San Francisco
Pankaj VatsPankaj Vats, PhD, Senior Bioinformatics/Genomics Scientist, NVIDIA
Jonathan M. CarlsonJonathan M. Carlson, PhD, General Manager, Life Sciences, Microsoft Health Futures

ARTIFICIAL INTELLIGENCE FOR PRECISION MEDICINE

4:10 pm Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

4:15 pm FIRESIDE CHAT: Artificial Intelligence Innovation for Precision Medicine
Eric TopolEric Topol, MD, Founder and Director, Scripps Research Translational Institute; Executive Vice President and Professor, Scripps Research
Mara G. AspinallMara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
A visionary at the intersection of medicine and technology, Dr. Eric Topol articulates the big picture for radical improvement in healthcare through personalized and data-driven medicine. Eric published three books, over 1,200 peer reviewed publications, and provides his reasoned perspective on medical AI frequently on social media. We will discuss his views on the current state of precision medicine and artificial intelligence, including generative AI in medicine, diagnostics, and clinical trials.

4:45 pm PANEL DISCUSSION: AI in Precision Medicine: Innovation and Growth Opportunities
PANEL MODERATOR:
Mara G. AspinallMara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
The convergence of artificial intelligence (AI) and precision medicine promises to revolutionize health care. Generative AI, machine learning, and sophisticated computational power promise to enable clinical decision support and diagnostics, support drug development, and optimize personalized medicine.

PANELISTS:
Eric TopolEric Topol, MD, Founder and Director, Scripps Research Translational Institute; Executive Vice President and Professor, Scripps Research
Michael J. AlkireMichael J. Alkire, President and CEO, Premier, Inc.


Michael PelliniMichael Pellini, MD, General Partner, S32

 


Wednesday, March 27

THE STATE OF INNOVATION IN DIAGNOSTIC TESTING FOR PERSONALIZED MEDICINE

8:00 am Chairperson's Remarks
Edward Abrahams, PhD, President, Personalized Medicine Coalition

8:05 am Plenary Keynote Introduction
Beresford-PaulPaul Beresford, Vice President and General Manager, CDx, Agilent Technologies


8:15 am PANEL DISCUSSION: The State of Innovation in Diagnostic Testing for Personalized Medicine
PANEL MODERATOR:
Edward AbrahamsEdward Abrahams, PhD, President, Personalized Medicine Coalition
Integrating diagnostics into clinical care faces numerous challenges, including regulatory, reimbursement, and clinical adoption among others, before the promise of personalized medicine can be realized. This panel, with support from the Personalized Medicine Coalition, will consider these barriers and propose solutions to overcome them.

PANELISTS:
Beresford-PaulPaul Beresford, Vice President and General Manager, CDx, Agilent Technologies
Peter BachPeter Bach, MD, CMO, Delfi Diagnostics
Christopher ConnChristopher Conn, PhD, Global Director, Clinical Biomarkers & Diagnostics, Diagnostics Strategy Lead, Amgen
Jeffrey VenstromJeffrey Venstrom, MD, CMO, GRAIL
Helmy EltoukhyHelmy Eltoukhy, PhD, Co-CEO, Guardant Health


Register Now
March 26-27, 2024

AI in Precision Medicine

Implementing Precision Medicine

At-Home & Point-of-Care Diagnostics

Liquid Biopsy

Spatial Biology

March 27-28, 2024

AI in Diagnostics

Diagnostics Market Access

Infectious Disease Diagnostics

Multi-Cancer Early Detection

Single-Cell Multiomics